Rania Hathout

Prof. Dr. Rania Hathout

Pharmacy Ain Shams University
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AGAhmed S. Guinedi
Ahmed S. Guinedi
NMNahed D. Mortada
Nahed D. Mortada
SMSamar Mansour
Samar Mansour
Rania HathoutRania Hathout
Rania Hathout

1 March 2007 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
Rania HathoutRania Hathout
Rania Hathout
SMSamar Mansour
Samar Mansour
NMNahed D. Mortada
Nahed D. Mortada
AGAhmed S. Guinedi
Ahmed S. Guinedi

1 March 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
MMMina Mehanny
Mina Mehanny
Rania HathoutRania Hathout
Rania Hathout
AGAhmed S. Geneidi
Ahmed S. Geneidi
SMSamar Mansour
Samar Mansour

1 June 2019 in Carbohydrate Polymers
Verified
Journal Article
Closed access
HAHani Nasser Abdelhamid
Hani Nasser Abdelhamid
HEHaitham M. El-Bery
Haitham M. El-Bery
AMAbdelkader Metwally
Abdelkader Metwally
MEMohamed Elshazly
Mohamed Elshazly
Rania HathoutRania Hathout
Rania Hathout

1 November 2017 in Journal of Controlled Release
Verified
Journal Article
Open access
GDGuangsheng Du
Guangsheng Du
Rania HathoutRania Hathout
Rania Hathout
MNMaha Nasr
Maha Nasr
MNM. Reza Nejadnik
M. Reza Nejadnik
JTJing Tu
Jing Tu
JMJuha Mönkäre
Juha Mönkäre
In this study, we investigated the potential of intradermal delivery of nanoparticulate vaccines to modulate the immune response of protein antigen using hollow microneedles. Four types of nanoparticles covering a broad range of physiochemical parameters, namely poly (lactic-co-glycolic) (PLGA) nanoparticles, liposomes, mesoporous silica nanoparticles (MSNs) and gelatin nanoparticles (GNPs) were compared. The developed nanoparticles were loaded with a model antigen (ovalbumin (OVA)) with and without an adjuvant (poly(I:C)), followed by the characterization of size, zeta potential, morphology, and loading and release of antigen and adjuvant. An in-house developed hollow-microneedle applicator was used to inject nanoparticle suspensions precisely into murine skin at a depth of about 120μm. OVA/poly(I:C)-loaded nanoparticles and OVA/poly(I:C) solution elicited similarly strong total IgG and IgG1 responses. However, the co-encapsulation of OVA and poly(I:C) in nanoparticles significantly increased the IgG2a response compared to OVA/poly(I:C) solution. PLGA nanoparticles and liposomes induced stronger IgG2a responses than MSNs and GNPs, correlating with sustained release of the antigen and adjuvant and a smaller nanoparticle size. When examining cellular responses, the highest CD8+ and CD4+ T cell responses were induced by OVA/poly(I:C)-loaded liposomes. In conclusion, the applicator controlled hollow microneedle delivery is an excellent method for intradermal injection of nanoparticle vaccines, allowing selection of optimal nanoparticle formulations for humoral and cellular immune responses.

1 June 2010 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Rania HathoutRania Hathout
Rania Hathout
TWTim Woodman
Tim Woodman
SMSamar Mansour
Samar Mansour
NMNahed D. Mortada
Nahed D. Mortada
AGAhmed S. Geneidi
Ahmed S. Geneidi
RGRichard H. Guy
Richard H. Guy